Report reveals gap between rare-disease drug spending, need
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
Archives for March 11, 2021
Thermo Fisher Scientific expands DTP trial service offerings
The direct-to-patient service is designed to support trials and help to minimize trial length and costs, while boosting enrollment and participation rates.